FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 213 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... December 11, 2020 Load more HOT NEWS Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... Beating cancer by improving the public’s health: the road ahead in...
